New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody

Breast Cancer

Volumn 7, Issue 4, 2000, Pages 350-357

  Sakamoto, Goi ^a   Mitsuyama, Shoshu ^b  

^a CANCER INSTITUTE   (Japan)

^b Kitakyushu MumcipaIMedical Center   (Japan)

Author keywords

Adjuvant chemotherapy; Adriamycin; Docetaxel; Epirubicin; Herceptin; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ARTICLE; BREAST TUMOR; CLINICAL TRIAL; DRUG ANTAGONISM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; PROGNOSIS; PROTO ONCOGENE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 0034564588     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02966404     Document Type: Conference Paper

References (0)